登录

安捷伦任命Simon May领导诊断和基因组学小组

Agilent Names Simon May to Lead Diagnostics and Genomics Group

businesswire | 2024-04-29 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6..

加利福尼亚州圣克拉拉——(商业新闻短讯)——安捷伦科技有限公司(纽约证券交易所:A)今天宣布,西蒙·梅被任命为该公司诊断与基因组学集团(DGG)的总裁。曾任Bio-Rad实验室执行副总裁兼生命科学小组主席的梅将于5月6日加入安捷伦。。

“We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s deep technical knowledge, his broad range of experience, and his career-long focus on strategy, continuous improvement and operational excellence are critical additions to our DGG organization as we capitalize on the opportunities that lie in front of us in helping our customers bring great science to life.”.

首席运营官兼当选首席执行官PadraigMcDonnell表示:“我们很高兴欢迎西蒙·梅加入安捷伦团队。”。“西蒙深厚的技术知识、丰富的经验,以及他长期专注于战略、持续改进和卓越运营的职业生涯,是我们DGG组织的重要补充,因为我们利用摆在我们面前的机会,帮助客户将伟大的科学带入生活。”。

Prior to his role with the Life Science Group, Simon served in other positions at Bio-Rad, including senior vice president and general manager of the Digital Biology Group, and as senior vice president of Global Commercial Operations. Before joining Bio-Rad in 2014, May held positions at Thermo Fisher Scientific for 10 years as well as MWG Biotech.

在加入生命科学集团之前,西蒙曾在Bio-Rad担任其他职位,包括数字生物集团高级副总裁兼总经理,以及全球商业运营高级副总裁。在2014年加入Bio-Rad之前,May曾在Thermo Fisher Scientific和MWG Biotech任职10年。

He began his career in laboratory roles before moving into sales, product-management, and business-leadership positions..

在进入销售、产品管理和业务领导岗位之前,他以实验室角色开始职业生涯。。

May earned his bachelor’s degree and his doctorate in genetics/molecular biology from England’s University of Liverpool, where he later spent two years as a postdoctoral research fellow.

梅在英国利物浦大学获得了遗传学/分子生物学学士学位和博士学位,后来在那里做了两年博士后研究员。

About Agilent Technologies

关于安捷伦科技

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions.

安捷伦科技有限公司(纽约证券交易所代码:A)是分析和临床实验室技术的全球领导者,提供见解和创新,帮助我们的客户将伟大的科学带入生活。安捷伦的全套解决方案包括仪器、软件、服务和专业知识,为客户最具挑战性的问题提供可靠的答案。

The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook..

2023财年,该公司实现收入68.3亿美元,在全球拥有约18000名员工。有关安捷伦的信息,请访问www.Agilent.com。要获得最新的安捷伦新闻,请订阅安捷伦新闻编辑室。在LinkedIn和Facebook上关注安捷伦。。

推荐阅读
发现

DNA合成技术研究商Elegen获得3500万美元B轮融资,加速向临床制造领域扩张

----
businesswire 2024-05-14 18:00

2024年4月全球医疗健康领域投融资月报

动脉网APP 2024-05-11 16:06

安捷伦推出NovoCyte Opteon光谱流式细胞仪

生命科学产业观察 2024-05-09 11:45

businesswire

6544篇

最近内容 查看更多

平行生物启动临床试验加速药物发现

5 小时后

athenahealth推出新的定制专业解决方案套件,以简化美国的医疗保健实践

5 小时后

Humana&Privia Medical Group–Georgia与Bamboo Health合作获得KLAS Research Points of Light奖

5 小时后

相关公司查看更多

Agilent Technologies

诊断产品提供商

立即沟通

产业链接查看更多